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Abstract
Orexin is a neuropeptide contained in neurons from several hypothalamic nuclei 
that project throughout the forebrain analogously to monoamines synthesized by 
brainstem nuclei. Orexin, like 5-hydroxytryptamine (5-HT), norepinephrine (NE), 
dopamine (DA), histamine and acetylcholine (ACh) exerts prominent effects on 
the sleep-wake cycle of all mammals. Activation of the orexin2 receptor appears 
to induce spontaneous excitatory synaptic currents (EPSCs) on layer V pyramidal 
neurons due to release of glutamate from thalamocortical terminals similar to acti-
vation of 5-HT2A and α1-adrenergic receptors. Layer V pyramidal cells are the major 
descending output cell in the prefrontal cortex with projections to the thalamus, 
striatum, amygdala, brainstem and spinal cord. In keeping with salient modulation 
of prefrontal cortical physiology, orexin2 receptor antagonists exert similar effects 
to 5-HT2A receptor antagonists in suppressing hallucinogen (e.g., DOI)-induced 
head twitches and producing antidepressant-like effects on the differential-
reinforcement-of-low-rate 72-s (DRL 72-s) schedule of reinforcement. Currently, 
there is both negative and some preliminary positive evidence that blocking orexin2 
receptors may result in antidepressant efficacy in patients with major depressive 
disorder. Overall, the treatment of mood disorders is an additional potential indica-
tion for orexin receptor antagonists beyond simply improving sleep.
Keywords: antidepressant drug screens, excitatory postsynaptic potential currents 
(EPSCs), DOI-induced head twitches, differential-reinforcement-of-low-rate 72-s 
(DRL 72-s) behavior, LSN2424100, layer V pyramidal neurons, prefrontal cortex, 
thalamocortical axons
1. Introduction
Only approximately 50–60% of patients experience an antidepressant response 
when treated with selective reuptake inhibitors (SSRIs) or serotonin-norepinephrine 
reuptake inhibitors (SNRIs) [1–3]. Even those patients that do respond often continue 
to experience residual symptoms such as insomnia and cognitive dysfunction [4–7]. 
Thus, novel antidepressant medications are needed that treat a broader expanse 
of symptoms or are effective in patients that have failed several different classes of 
antidepressants drugs.
The primary well-documented augmentation treatment for depressed patients 
already on SSRIs or SNRIs are atypical antipsychotics (aripiprazole, quetiapine, 
Antidepressants - Preclinical, Clinical and Translational Aspects
2
risperidone or olanzapine) and less so for mirtazapine/mianserin [8–12]. The 
common pharmacological action shared by these medications is blockade of 5-HT2A 
receptors [13]. Blockade of 5-HT2A receptors may also be a key pharmacological 
feature for most tricyclic antidepressant drugs which explain their greater anti-
depressant efficacy compared to SSRIs [14–17]. However, side effects especially 
problematic for augmentation of SSRIs/SNRIs with atypical antipsychotic drugs are 
weight gain and extrapyramidal symptoms. Thus, discovery of a drug targeted on 
key neurocircuitry modulated by 5-HT2A receptors is one strategy to develop a novel 
antidepressant medication.
Given that pathophysiology of mood disorders appears to involve the prefrontal 
cortex and associated macrocircuits, an obvious candidate brain region to pro-
vide a context for 5-HT2A receptor blockade at augmenting the effects of SSRIs/
SNRIs is the prefrontal cortex [18–21]. In particular, layer V pyramidal neurons 
can effectively modulate important cortical circuits (including corticothalamic, 
corticostriatal, cortico-amydalar and cortico-brainstem) that impact mood, cogni-
tion/executive function, sleep and appetite [22, 23]. One aspect of 5-HT2A receptor 
function largely restricted to layer V pyramidal cells is increasing the frequency 
of spontaneous excitatory postsynaptic currents/potentials (EPSC/EPSPs) onto 
the dendritic branches [24]. This effect appears to be mediated by AMPA receptor 
stimulation of directly on the layer V pyramidal cells [24, 25]. Lesion studies have 
suggested that 5-HT2A receptor activation is releasing glutamate from thalamocorti-
cal terminals arising from the “non-specific” midline and intralaminar thalamic 
nuclei [26, 27]. There appear to be hot spots in layer I and layer Va where focal 
5-HT-induced release of glutamate sensitive to the sodium channel blocker tetrodo-
toxin (TTX) occurs, although an amplification of postsynaptic currents, including 
TTX-sensitive sodium currents [24]. A number of Gi/Go-coupled GPCRs (including 
mGlu2, mGlu4, μ-opioid, adenosine A1 receptors) also suppresses 5-HT- or DOI-
induced glutamate release from these terminals [28–33]. Several other Gq/G11-
coupled GPCRs (α1-adrenergic receptors and mGlu5 receptors) also appear to induce 
glutamate release onto layer V pyramidal neurons that are suppressed by the sodium 
channel blocker TTX, μ-opioid agonists, and AMPA receptor antagonists [34, 35]. 
This rich pharmacological modulation of 5-HT2A receptor-mediated electrophysi-
ological effects on dendritic integration for the principle output neurons in the 
prefrontal cortex provides heuristic promise for drug discovery efforts with respect 
to major psychiatric disease, including mood disorders and schizophrenia [36, 37].
The increase in spontaneous EPSC/EPSPs upon layer V pyramidal cells induced 
by 5-HT2A receptor activation may be associated with other electrophysiological, 
biochemical and behavioral effects involving the medial prefrontal cortex (mPFC). 
On an electrophysiological level, electrical stimulation of the white matter below 
the cortex appears to result in an induction of “late” EPSC/EPSPs during washout 
after application of 5-HT or when the phenethylamine hallucinogen DOI is bath-
applied to the cortical slice [38]. These late EPSCs are also suppressed by a range of 
neurotransmitter receptors that suppress spontaneous 5-HT-induced EPSCs such 
as agonists for mGlu2, μ-opioid, and adenosine A1 receptors [30, 32]. There are 
also some differences between these two electrophysiological responses as NMDA 
receptor stimulation appears important for the electrical stimulation/DOI-evoked 
responses unlike the spontaneous 5-HT-induced EPSC/EPSPs [39].
Secondly, systemic DOI administration also induces a range of immediate-early 
gene-like signals in the prefrontal cortex/neocortex that are also suppressed by 
activation of mGlu2 autoreceptors and appear dependent on glutamate release from 
thalamocortical terminals [40–45]. This effect of prefrontal cortical 5-HT2A recep-
tor activation is relatively sparsely studied compared to the electrophysiological or 
behavioral sequelae.
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Third, either systemic administration or local prefrontal cortical administration 
of agonists for 5-HT2A receptors induces a robust increase in the frequency of head 
twitches (a behavior infrequently observed under baseline condition) [46, 47]. 
Agonists or positive allosteric modulators of mGlu2, mGlu4, μ-opioid, adenosine A1 
receptors also suppress DOI-induced head twitches [28, 31, 48–52]. Naturally, these 
head twitches induced by direct 5-HT2A receptor agonists are also suppressed by 
a number of antidepressant drugs that potently block 5-HT2A receptors or down-
regulate 5-HT2A receptors such as mirtazapine [53], mianserin [54–57], trazodone 
[55, 58–60], nefazodone [58, 61] and tricyclic antidepressants [55, 57, 62–68] Some 
of the tricyclic antidepressants are active only with chronic daily administration. 
While the antidepressant and monoamine oxidase inhibitor (MAOI) tranylcypro-
mine does not directly bind to 5-HT2A receptors, chronic daily administration of 
this antidepressant has been found to suppress 5-methoxy-N,N-dimethyltrypt-
amine-induced head twitches under conditions associated with a down-regulation 
of 5-HT2A receptors [63]. The clinical lore regarding μ-opioid receptor agonists and 
potential antidepressant action is intriguing in light of effects for this class of drugs 
on DOI-induced head twitches have been discussed elsewhere [36].
Finally, an argument was advanced recently that the basis for detecting antide-
pressant-like drug effects on the operant differential-reinforcement-of-low-rate 
72-s (DRL 72-s) schedule may be related to the biology of a range of neurotrans-
mitter systems that interact with the 5-HT2A receptor in the prefrontal cortex to 
modulate motor impulsivity [69, 70]. As expected from the similar effects of 5-HT2A 
receptor antagonists compared to mGlu2 receptor positive allosteric modulators 
(PAMs) and also to adenosine A1 receptor agonists for the prefrontal electrophysi-
ology discussed above, 5-HT2A receptor antagonists, mGlu2 receptor PAMs and 
adenosine A1 receptor agonists all test similar to known antidepressant drugs in rats 
performing under the DRL 72-s schedule [51, 71–77].
The underlying thesis of this chapter is that understanding how other neu-
rotransmitter systems interact with 5-HT2A receptors in the medial prefrontal cor-
tex on an electrophysiological, biochemical and behavioral scale may help discover 
novel antidepressant drugs. Orexin (OX) receptor agonists/antagonists appear to 
be one such neurotransmitter system that interacts with critical biological aspects 
of 5-HT2A receptor activation/blockade in thalamocortical pathways influencing 
the principle output (layer V pyramidal cells) of the prefrontal cortex in a manner 
suggesting that OX2 receptor antagonists are putative antidepressant medications.
2. Orexin-2 receptor blockade and putative antidepressant action
The orexins are two peptide neurotransmitters produced in several nuclei within the  
lateral hypothalamus which are intimately involved in arousal and reward [78]. The 
name “orexin” was originally coined from the Greek word “orexis” when the orexin/
hypocretin peptides were studied for effects on appetite. However, the more salient 
biological aspect of the orexin system later was realized to be altering sleep and 
arousal. More specifically, mutations of genes for the orexin-2 (OX2) receptor, orexin 
peptides, and loss of orexin-containing hypothalamic cell bodies were demon-
strated to be the genetic cause of narcolepsy in canines, mice and humans. The first 
approved medication targeting the orexin system, suvorexant, blocks both orexin-1 
(OX1) and OX2 receptors as a dual orexin receptor antagonist (DORA) and is indi-
cated for the treatment of insomnia [78, 79]. Several other DORAs have been shown 
to be efficacious in treating primary insomnia [80–82]. The overlapping and diverg-
ing distribution for the OX1 and OX2 mRNA and protein has inspired several decades 
of past/ongoing research exploring these receptors for sleep, arousal, feeding, 
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alcohol and drug self-administration, stress, anxiety and depression models [83].  
The involvement of OX2 receptors in arousal together with the presence of OX2 
receptor mRNA in the non-specific midline and intralaminar thalamic nuclei and 
the interactions of the orexin system with brainstem nuclei with overlapping mono-
amine projections makes the OX2 receptor an especially interesting target for mood 
disorder therapeutics [78, 83]. As discussed below, OX2 or hypocretin-2 receptor 
blockade appears to be a mechanism of action that provides a means of testing the 
hypothesis discussed above where a drug appropriately modifying multiple levels 
of biological effects for 5-HT2A receptor activation in the mPFC would be a putative 
antidepressant medication.
Electrophysiological effects of OX2 receptor activation in the prefrontal cortex 
appear to parallel certain effects of 5-HT2A receptor activation when recording 
from layer V pyramidal neurons. The orexin-B (hypocretin-2) peptide was found to 
increase spontaneous EPSC/EPSPs in layer V pyramidal neurons of the prefrontal 
cortex that were blocked by postsynaptic AMPA receptor antagonists as well as by 
TTX and u-opioid agonists on the presynaptic side similar to the case for 5-HT2A 
receptor stimulation [84]. Experiments to delineate the origin of afferents in the 
PFC from which orexin induced glutamate release from suggested that the cells of 
origin were in the midline and intralaminar thalamic nuclei [84]. Further, the rela-
tive potency for orexin-B compared to orexin-A (hypocretin-1) at inducing spon-
taneous OX-induced EPSCs/EPSPs in PFC layer V pyramidal cells is similar to that 
found in the intralaminar and midline thalamic nuclei with OX2, not OX1, receptor 
responses [84–86]. The tetrodotoxin sensitivity of the orexin-induced EPSCs/
EPSPs is in keeping with earlier studies suggesting that thalamocortical projections 
from these “non-specific” thalamic nuclei associated with arousal were prone to 
the generation of terminal spikes as previously suggested [87, 88]. This dependence 
on thalamocortical pathways originating in the midline and intralaminar thalamic 
nuclei and terminating in layers I and Va of the prefrontal cortex is consistent with 
features for the spontaneous 5-HT-induced EPSCs/EPSPs [26, 27]. One difference 
between OX-induced spontaneous EPSCs and 5-HT-induced EPSCS is that OX does 
not appear to induce postsynaptic depolarization (consistent with absence of OX2 
mRNA in layer V pyramidal cells) unlike the case for 5-HT2A receptor activation in 
the majority of layer V pyramidal cells [84, 89]. However, studies characterizing the 
ability of orexin-B induced EPSCs/EPSPs to be blocked with selective OX2 receptor 
antagonists or selective OX1 receptor antagonists would be useful to unambiguously 
identify the OX receptor subtype involved in this response.
Limited work has been done exploring effects of OX2 receptor antagonists on 
immediate early gene (IEG-like) responses in the prefrontal cortex. However, the 
OX2 receptor antagonist LSN2424100 did suppress restraint stress-induced increases 
in c-Fos protein expression without having any effects on baseline Fos protein 
expression in the home cage [90]. These effects of the OX2 receptor antagonist 
LSN2424100 on restraint stress-induced increases Fos expression in the prelimbic 
cortex are similar to an effect of the mGlu2 receptor agonist LY354740 on restraint 
stress-induced increases in Fos expression [45]. As discussed above, 5-HT2A receptor 
agonists induce a number of immediate IEG-like responses in the prefrontal cortex. 
Activation of mGlu2 receptors appears to suppress the DOI-induced increases in a 
number of IEG-like responses in the prefrontal cortex [40, 41, 44, 91].
Modulation of 5-HT2A receptor agonist-induced head twitches is a behavioral 
measure that is suppressed by a range of antidepressants blocking/regulating 
5-HT2A receptors as discussed above; these DOI-induced head twitches are also 
suppressed by the selective OX2 receptor antagonist LSN2424100 (Figure 1). 
LSN2424100 possesses approximately 200-fold functional OX2 receptor antago-
nist activity at both human recombinant OX2 vs. OX1 receptors or rat OX2 vs. OX1 
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receptors [90]. Administration of LSN2424100 (10 mg/kg, i.p.) 30 min prior to 
administration of DOI (3 mg/kg, i.p.) with behavioral observations beginning 
5 min later for a 30 min period resulted in over a 67% statistically significant reduc-
tion in the frequency of DOI-induced head twitches in CD-1 mice (n = 8/group;  
Figure 1) using conditions/methods/statistical analyses reported elsewhere in 
greater detail [52]. Head twitches were observed in 8/8 vehicle/DOI treated mice 
but in only 3/8 LSN2424100/DOI treated mice (p < 0.05, Fisher’s Exact Test). This 
experiment demonstrating that a Gq/G11-coupled GCPR OX2 receptor antagonist 
(like 5-HT2A receptor antagonists) suppress DOI-induced head twitches fits in with 
evidence that agonists or positive allosteric modulators of Gi/Go-coupled GCPRs 
(mGlu2, mGlu4, adenosine A1, and μ-opioid receptors) similarly suppress DOI-
induce head twitches [28, 31, 48, 50, 52, 92, 93]. Thus, the effects of these drugs on 
spontaneous EPSCs/EPSPs upon layer V pyramidal neuron apical dendrites in layers 
I and Va of the prefrontal cortex all produce directionally consistent effects on DOI-
induced head twitches [37]. These results imply that adequate orexin, glutamate, 
adenosine and endogenous opioid release is present from or onto thalamocortical 
afferents under the in vivo experimental conditions employed to engender salient 
changes in dendritic integration of the principle output layer V pyramidal cells.
OX2 receptor antagonists also appear to modulate at least certain aspects of execu-
tive function mediated by the prefrontal cortex, namely impulsivity and biasing oper-
ant responding for DRL schedules in rodents [69, 90]. The OX2 receptor antagonist 
LSN2424100 increased reinforcers obtained and decreased total responses by Sprague-
Dawley rats performing under a DRL 72-s schedule of reinforcement (Figure 2)  
[90]. These antidepressant-like responses were largely replicated in wild-type CD-1 
mice and OX1 receptor knockout mice responding on a DRL 36-s schedule of rein-
forcement rate [90]. However, no changes in the reinforcement rate or response rate 
Figure 1. 
The effect of (±)-DOI (3 mg/kg, i.p.) and the selective OX2 receptor antagonist LSN2424100 (10 mg/kg, i.p.) 
on head twitches in CD-1 wild-type mice observed for 30 min following drug administration. LSN2424100 was 
administered 30 min prior to DOI. Each bar represents the mean (± SEM) of eight mice. Significantly different 
from the mean number of head twitches for the vehicle/DOI group, * p < 0.05. Significantly different from the 
number of mice displaying head twitches for the vehicle/DOI group, # p < 0.05 by the Fisher exact test.
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were observed in OX2 receptor knockout mice when testing LSN2424100 doses up 
to twice as large as those used for wild-type and OX1 receptor knockout mice [90]. A 
similar antidepressant-like profile was observed in rats, wild-type CD-1 mice, and 
OX1 receptor KO mice with the non-selective OX1/OX2 receptor antagonist almorexant 
[90]. In contrast, a selective OX1 receptor antagonist failed to produce an antidepres-
sant-like response in rats performing on a DRL 72-s schedule or wild type mice or 
OX2 receptor knockout mice responding on a DRL 36-s schedule [90]. However, the 
well-established tricyclic antidepressant drug imipramine tested as expected in these 
experiments as a positive control (e.g., antidepressant-like effects) in Sprague-Dawley 
rats, wild-type mice, OX1 receptor knockout mice, or OX2 receptor KO mice trained to 
lever press under a DRL 72-s schedule (rats) or a DRL 36-s (mice) schedule.
3. Clinical trials with orexin receptor antagonists in patients with MDD
Thus far only a single small double-blind, placebo-controlled, diphenhydr-
amine-controlled, parallel group, phase 1b/2a trial of a selective OX2 receptor 
antagonist, JNJ-42847922/MIN-202 or seltorexant, has been conducted [94]. 
Figure 2. 
The antidepressant-like effect of LSN2424100 on male Sprague-Dawley rats (n = 7) stably performing under 
a DRL 72-s schedule. The top graph shows the effects of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/
kg, i.p.) on the number of reinforcers obtained after vehicle/drug was administered 1 hour prior to the daily 
session. The bottom graph shows the effect of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/kg, i.p.) on 
the total number of responses. The dotted line shows the control reinforcement and response rate and * denotes 
data points significantly different from control (p < 0.05) (this figure was adapted from data presented by Fitch 
et al. [90]).
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Only 47 men and women with a diagnosis of MDD (DSM-IV) were randomized 
to received either diphenhydramine, 25 mg q.d. (n = 13), seltorexant, 20 mg 
q.d. (n = 22) or placebo (n = 12) for 10 nights. Sleep polysomnography was also 
performed to provide objective assessment of improvements on sleep. There were 
improvements from baseline in the seltorexant treatment group for the HAMD-17 
total score (−3.6 points) as well as the HAM-17 adjusted total score accounting 
for sleep improvement in addition to changes in the HAMD-6 item score (−1.5 
points). This resulted in effect sizes of −0.48, −0.55 and − 1.05 for the OX2 receptor 
antagonist compared to placebo. However, one caveat is that the subjects assigned to 
the histamine H1 receptor antagonist diphenhydramine showed highly comparable 
improvement compared to placebo as did seltorexant. To answer these questions/
concerns, a phase 2b randomized, double-blind parallel group, placebo-controlled, 
adaptive dose-finding trial for seltorexant adjunctive treatment to antidepres-
sants scheduled to enroll about 280 adult subjects at 85 US, European, Russian and 
Japanese sites began in September 2017 (NCT03227224).
The only other MDD clinical trial for an OX receptor antagonist was negative 
[95]. Filorexant (MK-6096), a dual orexin receptor antagonist, was evaluated in a 
6-week, double-blind, placebo-controlled, parallel-group phase 2a proof-of-concept 
trial where subjects with MDD were randomized 1:1 to once-daily oral filorexant 
10 mg or matching placebo. Subjects on antidepressants continued to take their 
prescribed antidepressant for the duration of the trial. This study was stopped 
after enrolling 129 (40%) of a planned 326 subjects. Less than a 1 point numerical 
improvement was observed for filorexant compared to placebo using the mean 
change from baseline to week 6 MADRS total score. Exploratory analyses also 
failed to reveal statistically significant changes in the Insomnia Severity Index (ISI). 
Regarding safety, there were no deaths, drug-related serious adverse events (SAEs) 
and only one discontinuation due to AEs in both treatment groups. There were no 
other problematic safety issues reported.
This negative filorexant MDD study may be related to an issue of inadequate 
power as the planned study was designed with 80% power to detect a 3.5-point 
difference between treatments with a 2-sided 5% level of significance and a fully 
enrolled trial. However, the enrollment of only 129 subjects while using 61 sites 
(United States, Canada, Finland, France, Germany, Norway and Sweden) speaks 
to the recruitment challenges in this study. The dose chosen for this MDD trial 
appears reasonable based on positive effects reported for filorexant in a phase 2 
randomized, double-blind, placebo-controlled adaptive crossover polysomnogra-
phy dose-ranging study evaluating approximately 80 subjects each at nightly doses 
of 2.5, 5 and 10 mg [81]. All doses showed significant effects on sleep efficiency and 
wakefulness after persistent sleep onset while the two higher doses demonstrated 
significant effects on sleep onset. Filorexant was also well tolerated in this insomnia 
trial as well [81].
Preclinical results suggest that the combined OX1/OX2 receptor antagonism 
should not have compromised potential antidepressant action in patients with 
MDD. Namely, the OX1/OX2 receptor antagonist almorexant acted similarly to the 
OX2 receptor antagonist LSN2424100 and the known tricyclic antidepressant imip-
ramine in rats and mice performing on DRL 72-s or DRL 36-s schedules [90]. In 
addition, the non-selective OX receptor antagonist almorexant also tested similarly 
to known antidepressants in mice subjected to unpredictable chronic mild stress 
(UCMS) and then evaluated with the tail suspension test, the resident-intruder 
test, and the elevated plus maze [96]. However, opposing antidepressant-like and 
“pro-depressant”-like effects were observed in OX1 and OX2 receptor knockout 
mice, respectively, studied with the forced swim paradigm [97]. In this same study, 
the selective OX1 receptor antagonist SB-334867 also exerted an antidepressant like 
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Figure 3. 
The model where activation of 5-HT2A or OX2 receptors depolarizes and releases glutamate from non-specific 
thalamocortical inputs to layer I and Va of the apical dendrites from layer V pyramidal neurons. The majority 
of 5-HT2A receptors, apart from a minority of presynaptic receptors and those on GABAergic interneurons, are 
present on and also directly depolarize layer V pyramidal neurons. Other glutamatergic receptors (mGlu2 and 
mGlu4), μ-opioid receptors and adenosine A1 receptors that suppress the EPSCs/EPSPs induced by activation 
of 5-HT2A and OX2 receptors appear to be present on non-specific thalamocortical afferents. This circuitry 
(with additional positive modulator receptor such as mGlu5 and NK3 receptors and also additional negative 
modulators such as β2-adrenergic receptors) appears to underlie a similar valence of action for all these 
receptors for a behavior mediated by activation of 5-HT2A receptors in the prefrontal cortex, DOI-induced 
head twitches. This circuitry also appears to underlie impulsive behavior (DRL 72-s behavior) where a similar 
valence of GPCR mediated effects appears to drive antidepressant-like effects on this screening behavior as 
DOI-induced head twitches and 5-HT-induced EPSCs.
effect in the forced swim test. No data has been published suggesting that selec-
tive OX2 receptor antagonists test as antidepressants in rodent forced swim tests. 
Nevertheless, the balance of data are consistent with the hypothesis that adequate 
blockade of both OX1 and OX2 receptors, or OX2 receptors alone, should improve 
depressive symptoms in patients with MDD.
4. Conclusions
Activation of 5-HT2A receptors or OX2 receptors appears to induce glutamate 
release from thalamocortical terminals with cell bodies originating in the midline 
and intralaminar thalamic nuclei when recording from prefrontal cortical layer 
V pyramidal neurons (Figure 3). This 5-HT and orexin-B-induced glutamate 
release appears to dependent action potentials in the presynaptic terminals judging 
from the TTX-induced blockade of the 5-HT- or orexin-induced EPSC/EPSPs as 
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suggested previously for non-specific thalamocortical axons. Apical dendritic layer 
V pyramidal AMPA receptors appear to be activated postsynaptic to the thalamic 
terminals. The 5-HT or DOI-induced spontaneous EPSCs/EPSPs or DOI/electrically 
evoked EPSC/EPSPs also appear suppressed by mGlu2, mGlu4, adenosine A1, 5-HT-1-like 
and β2-adrenergic receptors.
Future work is required to establish that orexin-B-induced glutamate release 
from non-specific thalamic afferents is also suppressed by mGlu2, mGlu4, adenosine 
A1, 5-HT-1-like and β2-adrenergic receptors. Blockade of OX2 and 5-HT2A receptors 
also both appear to suppress DOI-induced head twitches, a behavioral response 
that appears to be mediated by activation of prefrontal cortical 5-HT2A receptors. 
A selective OX2 receptor antagonist tested similar to the tricyclic antidepressant 
imipramine in rats and mice responding under an operant DRL 72-s schedule of 
reinforcement. Another question for future preclinical research with rodent DRL 
behavior is whether blockade of OX2 receptors is additive/synergistic with tricyclic 
antidepressants or SSRIs in the same manner as blockade of 5-HT2A receptors. The 
ongoing clinical antidepressant trial with the OX2 receptor antagonist seltorexant 
are important to understanding whether the circuitry involving orexin-containing 
cells in the hypothalamus together with orexin-containing axon terminals in the 
intralaminar and midline thalamic nuclei and the prefrontal cortex are necessary 
and sufficient by themselves to augment the antidepressant effects of tricyclic 
antidepressants and SSRIs. If this ongoing and other clinical antidepressant trials 
with selective OX2 receptor antagonists or additional adequately powered clinical 
trials testing OX1/OX2 receptor antagonists are negative, then future work will be 
required to begin to ask whether additional actions of OX2 receptor antagonists 
in other circuitry are functionally opposed to the brainstem/thalamic/prefrontal 
cortical circuits.
Acknowledgements
The present manuscript was not supported by either Astellas or Lundbeck.
Conflict of interest
The authors were previously employed by Eli Lilly.
Antidepressants - Preclinical, Clinical and Translational Aspects
10
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Gerard J. Marek1*, Stephen Chaney2 and Mark J. Benvenga3
1 Astellas Pharma Global Development Inc., Northbrook, IL, USA
2 Eli Lily Research Laboratories, Indianapolis, IN, USA
3 Lundbeck, Sacramento, CA, USA
*Address all correspondence to: gerard.marek@astellas.com
11
Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens
DOI: http://dx.doi.org/10.5772/intechopen.82544
References
[1] Bradley AJ, Lenox-Smith AJ. Does 
adding noradrenaline reuptake 
inhibition to selective serotonin 
reuptake inhibition improve efficacy in 
patients with depression? A systematic 
review of meta-analysis and large 
randomized pragmatic trials. Journal 
of psychopharmacology (Oxford, 
England). 2013;27:740-758
[2] Cipriani A, Furukawa TA, Salanti G, 
Geddes JR, Higgins JP, Churchill R, et al. 
Comparative efficacy and acceptability 
of 12 new-generation antidepressants: 
A multiple-treatments meta-analysis. 
Lancet. 2009;373:746-758
[3] Papakostas GI, Charles D, Fava 
M. Are typical starting doses of the 
selective serotonin reuptake inhibitors 
sub-optimal? A meta-analysis of 
randomized, double-blind, placebo-
controlled, dose-finding studies in 
major depressive disorder. The World 
Journal of Biological Psychiatry. 
2010;11:300-307
[4] Mayers AG, Baldwin 
DS. Antidepressants and their effect 
on sleep. Human Psychopharmacology. 
2005;20:533-539
[5] Nakano Y, Baba H, Maeshima H, 
Kitajima A, Sakai Y, Baba K, et al. 
Executive dysfunction in medicated, 
remitted state of major depression. 
Journal of Affective Disorders. 
2008;111:46-51
[6] Paelecke-Habermann Y, Pohl J, 
Leplow B. Attention and executive 
function in remitted major depression 
patients. Journal of Affective Disorders. 
2005;89:125-135
[7] Winokur A, Gary KA, Rodner 
S, Rae-Red C, Fernando AT, Szuba 
MP. Depression, sleep physiology, and 
antidepressant drugs. Depression and 
Anxiety. 2001;14:19-28
[8] Blier P, Gobbi G, Turcotte JE, de 
Montigny C, Boucher N, Hebert C, 
et al. Mirtazapine and paroxetine in 
major depression: A comparison of 
monotherapy versus their combination 
from treatment initiation. European 
Neuropsychopharmacology. 
2009;19:457-465
[9] Carpenter LL, Yasmin S, Price LH. A 
double-blind placebo-controlled study 
of antidepressant augmentation with 
mirtazapine. Biological Psychiatry. 
2002;51:183-188
[10] Ferreri M, Lavergne F, Berlin I, 
Payan C, Peuch AJ. Benefits from 
mianserin augmentation of fluoxetine 
in patients with major depression 
non-responders to fluoxetine alone. 
Acta Psychiatrica Scandinavica. 
2001;103:66-72
[11] Han C, Wang S-M, Kato M, Lee 
S-J, Patkar AA, Masand PS, et al. 
Second-generation antipsychotics in the 
treatment of major depressive disorder: 
Current evidence. Expert Review of 
Neurotherapeutics. 2013;13:851-874
[12] Nelson JC, Papakostas GI. Atypical 
antipsychotic augmentation in major 
depressive disorders: A meta-analysis of 
placebo-controlled randomized trials. 
The American Journal of Psychiatry. 
2009;166:980-991
[13] Marek GJ, Carpenter LL, 
McDougle CJ, Price LH. Synergistic 
action of 5-HT2A antagonists and 
selective serotonin reuptake inhibitors 
in neuropsychiatric disorders. 
Neuropsychopharmacology. 
2003;28:402-412
[14] Marek GJ. Regulation of rat cortical 
5-hydroxytryptamine2A-receptor 
mediated electrophysiological responses 
by repeated daily treatment with 
electroconvulsive shock or imipramine. 
12
Antidepressants - Preclinical, Clinical and Translational Aspects
European Neuropsychopharmacology. 
2008;18:498-507
[15] Marek GJ. Cortical 
5-hydroxytryptamine2A-receptor 
mediated excitatory synaptic currents 
in the rat following repeated daily 
fluoxetine administration. Neuroscience 
Letters. 2008;438:312-316
[16] DUAG. Citalopram: Clinical 
effect profile in comparison with 
clomipramine—A controlled 
multicenter study. Psychopharmacology. 
1986;90:131-138
[17] DUAG. Paroxetine: A selective 
serotonin reuptake inhibitor 
showing better tolerance, but weaker 
antidepressant effect than clomipramine 
in a controlled multicenter study. 
Journal of Affective Disorders. 
1990;18:289-299
[18] Drevets WC. Functional 
neuroimaging studies of depression: The 
anatomy of melancholia. Annual Review 
of Medicine. 1998;49:341-361
[19] Drevets WC, Videen TO, Price JL, 
Preskorn SH, Carmichael ST, Raichle 
ME. A functional anatomical study 
of unipolar depression. Journal of 
Neuroscience. 1992;12:3628-3641
[20] Mayberg HS. Limbic-cortical 
dysregulation: A proposed model of 
depression. Journal of Neuropsychiatry 
& Clinical Neurosciences. 
1997;9(3):471-481
[21] Rajkowska G, Miguel-Hidalgo JJ,  
Wei J, Dilley G, Pittman SD, 
Meltzer HY, et al. Morphometric 
evidence for neuronal and glia 
prefrontal cell pathology in major 
depression. Biological Psychiatry. 
1999;45:1085-1098
[22] Price JL. Prefrontal cortical 
networks related to visceral function 
and mood. Annuals of New York 
Academy of Sciences. 1999;877:383
[23] Price JL, Drevets WC. 
Neurocircuitry of mood disorders. 
Neuropsychopharmacology. 
2010;35:192-216
[24] Aghajanian GK, Marek 
GJ. Serotonin induces excitatory 
postsynaptic potentials in apical 
dendrites of neocortical pyramidal 
cells. Neuropharmacology. 
1997;36(3/4):589-599
[25] Zhang C, Marek GJ. AMPA receptors 
involvement in 5-hydroxytryptamine2A 
receptor-mediated prefrontal cortical 
excitatory synaptic currents and DOI-
induced head shakes. Progress in Neuro-
Psychopharmacology & Biological 
Psychiatry. 2008;32:62-71
[26] Lambe EK, Aghajanian GK. The role 
of Kv1.2-containing potassium channels 
in serotonin-induced glutamate release 
from thalamocortical terminals in 
rat frontal cortex. The Journal of 
Neuroscience. 2001;21:9955-9963
[27] Marek GJ, Wright RA, Gewirtz 
JC, Schoepp DD. A major role 
for thalamocortical afferents in 
serotonergic hallucinogen receptor 
function in the rat neocortex. 
Neuroscience. 2001;105:379-392
[28] Benneyworth MA, Xiang Z, 
Smith RL, Garcia EE, Conn PJ, 
Sanders-Bush E. A selective positive 
allosteric modulator of metabotropic 
glutamate receptor subtype 2 blocks 
a hallucinogenic drug model of 
psychosis. Molecular Pharmacology. 
2007;72:477-484
[29] Marek GJ, Aghajanian GK. 
5-HT-induced EPSCs in neocortical 
layer V pyramidal cells: Suppression 
by μ-opiate receptor activation. 
Neuroscience. 1998;86:485-497
[30] Marek GJ, Wright RA, 
Schoepp DD, Monn JA, Aghajanian 
GK. Physiological antagonism between 
5-hydroxytryptamine2A and group 
13
Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens
DOI: http://dx.doi.org/10.5772/intechopen.82544
II metabotropic glutamate receptors 
in prefrontal cortex. The Journal of 
Pharmacology and Experimental 
Therapeutics. 2000;292:76-87
[31] Slawinska A, Wieronska JM, 
Stachowicz K, Marciniak M, Lason-
Tyburkiewicz M, Gruca P, et al. The 
antipsychotic-like effects of positive 
allosteric modulators of metabotropic 
glutamate mGlu4 receptors in rodents. 
British Journal of Pharmacology. 
2013;169:1824-1839
[32] Stutzman GE, Marek GJ, Aghajanian 
GK. Adenosine preferentially suppresses 
serotonin2A receptor-enhanced 
excitatory postsynaptic currents in layer 
V neurons of the rat medial prefrontal 
cortex. Neuroscience. 2001;105:55-69
[33] Zhang C, Marek GJ. Group III 
metabotropic glutamate receptor 
agonists selectively suppress 
excitatory synaptic currents in the 
rat prefrontal cortex induced by 
5-hydroxytryptamine2A receptor 
stimulation. The Journal of 
Pharmacology and Experimental 
Therapeutics. 2007;320:437-447
[34] Marek GJ, Zhang C. Activation of 
metabotropic glutamate 5 (mGlu5) 
receptors induces spontaneous 
excitatory synaptic currents in layer 
V pyramidal cells of the rat prefrontal 
cortex. Neuroscience Letters. 
2008;442:239-243
[35] Marek GJ, Aghajanian GK. 5-HT2A 
or α1-adrenoceptor activation induces 
excitatory postsynaptic currents in 
layer V pyramidal cells of the medial 
prefrontal cortex. European Journal of 
Pharmacology. 1999;367:197-206
[36] Marek GJ, Aghajanian GK. The 
electrophysiology of prefrontal 5-HT 
systems: Therapeutic implications 
for mood and psychosis. Biological 
Psychiatry. 1998;44:1118-1127
[37] Marek GJ. Interactions of 
Hallucinogens with the Glutamatergic 
System: Permissive Network Effects 
Mediated through Cortical Layer V 
Pyramidal Neurons. Current Topics 
in Behavioral Neuroscience. Berlin, 
Heidelberg: Springer; 2017
[38] Aghajanian GK, Marek 
GJ. Serotonin, via 5-HT2A 
receptors, increases EPSCs in layer 
V pyramidal cells of prefrontal 
cortex by an asynchronous mode of 
glutamate release. Brain Research. 
1999;825:161-171
[39] Lambe EK, Aghajanian 
GK. Hallucinogen-induced UP states in 
the brain slice rat prefrontal cortex: Role 
of glutamate spillover and NR2B-NMDA 
receptors. Neuropsychopharmacology. 
2006;31:1682-1689
[40] Gewirtz JC, Chen AC, Terwilliger 
R, Duman RC, Marek GJ. Modulation of 
DOI-induced increases in cortical BDNF 
expression by group II mGlu receptors. 
Pharmacology, Biochemistry, and 
Behavior. 2002;73:317-326
[41] Gonzalez-Maeso J, Ang RL, Yuen T, 
Chan P, Weisstaub NV, Lopez-Gimenez 
JF, et al. Identification of a serotonin/
glutamate receptor complex implicated 
in psychosis. Nature. 2008;452:93-97
[42] Gonzalez-Maeso J, Weisstaub NV, 
Zhou M, Chan P, Ivic L, Ang R, et al. 
Hallucinogens recruit specific cortical 
5-HT2A receptor-mediated signalling 
pathways to affect behavior. Neuron. 
2007;53:439-452
[43] Scruggs JL, Patel S, Bubser M, 
Deutch AY. DOI-induced activation of 
the cortex: Dependence upon 5-HT2A 
heteroceptors on thalamocortical 
glutamatergic neurons. The Journal of 
Neuroscience. 2000;20:8846-8852
[44] Wischhof L, Koch M. Pretreatment 
with the mGlu2/3 receptor 
agonist LY379268 attenuates DOI-
induced impulsive responding and 
Antidepressants - Preclinical, Clinical and Translational Aspects
14
regional c-Fos protein expression. 
Psychopharmacology. 2012;219:387-400
[45] Menezes MM, Marek GJ, Benvenga 
MJ, Chaney S, Svensson KA. The 
mGlu2/3 receptor agonist LY354740 
attenuates the restraint-stress induced 
Fos expression and DOI-induced Fos 
expression in prefrontal cortex. In: 
Neuroscience Meeting Planner Society 
for Neurocience. Chicago, IL: Society for 
Neuroscience; 2009. pp. 417-423
[46] Canal CE, Morgan D. Head-
twitch response in rodents induced 
by the hallucinogen 2,5-dimethoxy-4-
iodoamphetamine: A comprehensive 
history, a re-evaluation of mechanisms, 
and its utility as a model. Drug Test 
Analysis. 2012;4:556-576
[47] Willins DL, Meltzer HY. Direct 
injection of 5-HT2A receptor agonists 
into the medial prefrontal cortex 
produces a head-twitch response in 
rats. The Journal of Pharmacology 
and Experimental Therapeutics. 
1997;282:699-706
[48] Gewirtz JC, Marek GJ. Behavioral 
evidence for interactions between 
a hallucinogenic drug and group II 
metabotropic glutamate receptors. 
Neuropsychopharmacology. 
2000;23:569-576
[49] Klodzinska A, Bijak M, Tokarski 
K, Pilc A. Group II mGlu receptor 
agonists inhibit behavioral and 
electrophysiological effects of DOI in 
mice. Pharmacology Biochemistry & 
Behavior. 2002;73:327-332
[50] Marek GJ. Behavioral evidence 
for μ-opioid and 5-HT2A receptor 
interactions. European Journal of 
Pharmacology. 2003;474:77-83
[51] Marek GJ. Activation of adenosine1 
receptors induces antidepressant-like, 
anti-impulsive effects on differential 
reinforcement of low-rate 72-s behavior 
in rats. The Journal of Pharmacology 
and Experimental Therapeutics. 
2012;341:564-570
[52] Benvenga MJ, Chaney S, Baez M, 
Britton TC, Hornback WJ, Monn JA, 
et al. Metabotropic glutamate2 receptors 
play a key role in modulating head 
twitches induced by a serotonergic 
hallucinogen in mice. Frontiers in 
Pharmacology. 2018;9:208
[53] Rojoz Z. Effect of co-treatment with 
mirtazapine and risperidone in animal 
models of the positive symptoms of 
schizophrrenia in mice. Pharmacological 
Reports. 2012;64:1567-1572
[54] Blackshear MA, Sanders-Bush 
E. Serotonin receptor sensitivity after 
acute and chronic treatment with 
mianserin. The Journal of Pharmacology 
and Experimental Therapeutics. 
1982;221:303-308
[55] Friedman E, Cooper TB, Dallob 
A. Effects of chronic antidepressant 
treatment on serotonin receptor 
activity in mice. European Journal of 
Pharmacology. 1983;89:69-76
[56] Maj J, Rogoz Z, Skuza G, Sowinska 
H. The effect of repeated administration 
of imipramine, citalopram and 
mianserin on responsiveness of central 
serotonergic, alpha 2-adrenergic and 
cholinergic system in mice. Polish 
Journal of Pharmacology and Pharmacy. 
1989;41:313-319
[57] Ogren SO, Fuxe K, Agnati LF, 
Gustafsson JA, Jonsson G, Holm 
AC. Reevalulation of the indoleamine 
hypothesis of depression. Evidence for 
a reduction of functional activity of 
central 5-HT systems by antidepressant 
drugs. Journal of Neural Transmission. 
1979;46:85-103
[58] Taylor DP, Carter RB, Eison AS, 
Mullins UL, Smith HL, Torrente JR, 
et al. Pharmacology and neurochemistry 
15
Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens
DOI: http://dx.doi.org/10.5772/intechopen.82544
of nefazodone, a novel antidepressant 
drug. Journal of Clinical Psychiatry. 
1995;56(Suppl 6):3-11
[59] Clements-Jewery S, Robson PA, 
Chidley LJ. Biochemical investigations 
into the mode of action of trazodone. 
Neuropharmacology. 1980;19:1165-1173
[60] Cioli V, Corradino C, Piccinelli D, 
Rocchi MG, Valeri P. A comparative 
pharmacological study of trazodone, 
etoperidone and 1-(m-chlorophenyl)
piperazine. Pharmacological Research 
Communications. 1984;16:85-100
[61] Nacca A, Guiso G, Fracasso C, 
Cervo L, Caccia S. Brain-to-blood 
partition and in vivo inhibition 
of 5-hydroxytryptamine reuptake 
and quipazine-mediated behaviour 
of nefazodone and its main active 
metabolites in rodents. British Journal of 
Pharmacology. 1998;1998:1617-1623
[62] Wettstein JG, Host M, Hitchcock 
JM. Selectivity of action of typical 
and atypical anti-psychotic drugs as 
antagonists of the behavioral effects 
of 1-[2,5-dimethoxy-4-iodophenyl]-
2-aminopropane (DOI). Progress 
in Neuro-Psychopharmacology & 
Biological Psychiatry. 1999;23:533-544
[63] Goodwin GM, Green AR, Johnson 
P. 5-HT2 receptor characteristics in 
frontal cortex and 5-HT2 receptor-
mediated head-twitch behavior 
following antidepressant treatment to 
mice. British Journal of Pharmacology. 
1984;83:235-242
[64] Godfrey PP, McClue SJ, Young 
MM, Heal DJ. 5-hydroxytryptamine-
stimulated inositol phospholipid 
hydrolysis in the mouse cortex has 
pharmacological characteristics 
compatible with mediation via 5-HT2 
receptors but this response does 
not reflect altered 5-HT2 function 
after 5,7-dihydroxytryptamine 
lesioning or repeated antidepressant 
treatments. Journal of Neurochemistry. 
1988;50:730-738
[65] Pawlowski L, Ruczynska J, Gorka 
Z. Citalopram: A new potent inhibitor 
of serotonin (5-HT) uptake with 
central 5-HT-mimetic properties. 
Psychopharmacology. 1981;74:161-165
[66] Pawlowski L, Melzacka 
M. Inhibition of head twitch response 
to quipazine in rats by chronic 
amitriptyline but not fluvoxamine 
or citalopram. Psychopharmacology. 
1986;88:279-284
[67] Kawakami Y, Kitamura Y, Araki 
H, Kitagawa K, Suemaru K, Shibata K, 
et al. Effects of monoamine reuptake 
inhibitors on wet-dog shakes mediated 
by 5-HT2A receptors in ACTH-treated 
rats. Pharmacology, Biochemistry, and 
Behavior. 2005;81:65-70
[68] Kitamura Y, Araki H, Suemaru K, 
Gomita Y. Effects of imipramine and 
lithium on wet-dog shakes mediated by 
the 5-HT2A receptor in ACTH-treated 
rats. Pharmacology, Biochemistry, and 
Behavior. 2002;72:397-402
[69] Marek GJ, Day M, Hudzik TJ. The 
utility of impulsive bias and altered 
decision making as predictors of drug 
efficacy and target selection: Rethinking 
behavioral screening for antidepressant 
drugs. The Journal of Pharmacology 
and Experimental Therapeutics. 
2016;356:534-548
[70] O’Donnell JM, Marek GJ, Seiden 
LS. Antidepressant effects assessed 
using behavior maintained under a 
differential-reinforcement-of-low-rate 
(DRL) operant schedule. Neuroscience 
and Biobehavioral Reviews. 
2005;29:785-798
[71] Marek GJ, Li AA, Seiden 
LS. Selective 5-hydroxytryptamine2 
antagonists have 
antidepressant-like effects on 
Antidepressants - Preclinical, Clinical and Translational Aspects
16
differential-reinforcement-of-low-
rate 72-second schedule. The Journal 
of Pharmacology and Experimental 
Therapeutics. 1989;250(1):52-59
[72] Marek GJ, Martin-Ruiz R, Abo 
A, Artigas F. The selective 5-HT2A 
receptor antagonist M100907 enhances 
antidepressant-like behavioral 
effects of the SSRI fluoxetine. 
Neuropsychopharmacology. 
2005;30:2205-2215
[73] Marek GJ, Seiden LS. Effects of 
selective 5-hydroxytryptamine-2 and 
nonselective 5-hydroxytryptamine 
antagonists on the differential-
reinforcement-of-low-rate 72-second 
schedule. The Journal of Pharmacology 
and Experimental Therapeutics. 
1988;244(2):650-658
[74] Ardayfio PA, Benvenga MJ, Chaney 
SF, Love PL, Catlow J, Swanson SP, 





(M100907) attenuates impulsivity 
after both drug-induced disruption 
(dizocilpine) and enhancement 
(antidepressant drugs) of differential-
reinforcement-of-low-rate 72-s behavior 
in the rat. The Journal of Pharmacology 
and Experimental Therapeutics. 
2008;327:891-897
[75] Fell MJ, Witkin JM, Falcone JF, 




4-carboxamide (THIIC), a novel 
metabotropic glutamate 2 potentiator 
with potential anxiolytic/antidepressant 
properties: In vivo profiling suggests 
a link between behavioral and central 
nervous system neurochemical 
changes. The Journal of Pharmacology 
and Experimental Therapeutics. 
2011;336:165-177
[76] Nikiforuk A, Popik P, Drescher 
KU, van Gaalen M, Relo A-L, Mezler 
M, et al. Effects of a positive allosteric 
modulatory of group II metabotropic 
glutamate receptors, LY487379, on 
cognitive flexibility and impulsive-
like responding in rats. The Journal 
of Pharmacology and Experimental 
Therapeutics. 2010;335:665-673
[77] Li AA, Marek GJ, Hand TH, 
Seiden LS. Antidepressant-like effects 
of trazodone on a behavioral screen 
are mediated by trazodone, not the 
metabolite m-chlorophenylpiperazine. 
European Journal of Pharmacology. 
1990;177(3):137-144
[78] Gotter AL, Webber AL, Coleman 
PJ, Renger JJ, Windrow CJ. International 
Union of Basic and Clinical 
Pharmacology. LXXXVI. Orexin 
receptor function, nomenclature 
and pharmacology. Pharmacological 
Reviews. 2012;64:389-420
[79] Kuriyama A, Tabata H. Suvorexant 
for the treatment of primary insomnia: 
A systematic review and meta-analysis. 
Sleep Medicine Reviews. 2017;35:1-7
[80] Black J, Pillar G, Hedner J, Polo 
O, Berkani O, Mangialaio S, et al. 
Efficacy and safety of almorexant in 
adult chronic insomnia: A randomized 
placebo-controlled trial with an 
active reference. Sleep Medicine. 
2017;36:86-94
[81] Connor KM, Mahoney E, Jackson 
S, Hutzelmann J, Zhao X, Jia N, 
et al. A phase II dose-ranging study 
evaluating the efficacy and safety 
of the orexin receptor antagonist 
filorexant (MK-6096) in patients with 
primary insomnia. The International 
Journal of Neuropsychopharmacology. 
2016;19(8):1-10
[82] Murphy P, Moline M, Mayleben 
D, Rosenberg R, Zammit G, Pinner 
K, et al. Lemborexant, a dual orexin 
receptor antagonist (DORA) for the 
17
Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens
DOI: http://dx.doi.org/10.5772/intechopen.82544
treatment of insomnia disorder: Results 
from a Bayesian, adaptive, randomized, 
double-blind, placebo-controlled study. 
Journal of Clinical Sleep Medicine. 
2017;13:1289-1299
[83] Marcus JN, Aschkenasi CJ, Lee CE, 
Chemelli RM, Saper CB, Yanagisawa M, 
et al. Differential expression of orexin 
receptors 1 and 2 in the rat brain. The 
Journal of Comparative Neurology. 
2001;435:6-25
[84] Lambe EK, Aghajanian 
GK. Hypocretin (orexin) induces 
calcium transients in single 
spines postsynaptic to identified 
thalamocortical boutons in prefrontal 
slice. Neuron. 2003;40:139-150
[85] Bayer L, Eggermann E, Saint-
Mleux B, Machard D, Jones BE, 
Muhlethaler M, et al. Selective action 
of orexin (hypocretin) on nonspecific 
thalamocortical projection neurons. 
The Journal of Neuroscience. 
2002;22:7835-7839
[86] Lambe EK, Liu RJ, Aghajanian 
GKS. Hypocretin (orexin), and 
the thalamocortical activating 
system. Schizophrenia Bulletin. 
2007;33:1284-1290
[87] Gutnick MJ, Prince DA. 
Thalamocortical relay neurons: 
Antidromic invasion of spikes from a 
cortical epileptogenic focus. Science. 
1972;176:424-426
[88] Pinault D. Backpropogation of 
action potentials generated at ectopic 
axonal loci: Hypothesis that axon 
terminals integrate local environmental 
signals. Brain Research Reviews. 
1995;21:42-92
[89] Araneda R, Andrade R. 
5-Hydroxytryptamine2 and 
5-Hydroxytryptamine1A receptors 
mediate opposing responses on 
membrane excitability in rat 
association cortex. Neuroscience. 
1991;40(2):399-412
[90] Fitch TE, Benvenga MJ, Jesudason 
CD, Zink C, Vandergriff AB, Menezes 
MM, et al. LSN2424100: A novel, potent 
orexin-2 receptor antagonist with 
selectivity over orexin-1 receptors and 
activity in an animal model predictive of 
antidepressant-like efficacy. Frontiers in 
Neuroscience. 2014;8(5):1-11
[91] Menezes MM, Santini MA, 
Benvenga MJ, Marek GJ, Merchant 
KM, Mikkelsen JD, et al. The mGlu2/3 
receptor agonists LY354740 and 
LY379268 differentially regulate 
restraint-stress-induced expression 
of c-fos in rat cerebral cortex. 
Neuroscience Journal. 2013;736439:8
[92] Klodzinska A, Bijak M, Chojnacka-
Wojcik E, Kroczka B, Swiader M, 
Czuczwar SJ, et al. Roles of group 
II metabotropic glutamate receptor 
agonists in modulation of seizure 
activity. Naunyn-Schmiedeberg's 
Archives of Pharmacology. 
2000;361:283-288
[93] Marek GJ. Activation of adenosine1 
(A1) receptors suppresses head shakes 
induced by a serotonergic hallucinogen 
in rats. Neuropharmacology. 
2009;56:1082-1087
[94] Recourt K, Van Amerongen G, 
Jacobs G, Zuiker R, Luthringer R, 
Van der Ark P, et al. JNJ-42847922/
MIN-202, a selective orexin 2 
receptor antagonist, demonstrates 
beneficial effects on mood and sleep 
with major depressive disorder. 
European Neuropsychopharmacology. 
2017;27(Suppl. 4):S866
[95] Connor KM, Ceesay P, Hutzelmann 
J, Snavely D, Krystal AD, Trivedi MH, 
et al. Phase II proof-of-concept trial of 
the orexin receptor antagonist filorexant 
(MK-6096) in patients with major 
depressive disorder. The International 
Antidepressants - Preclinical, Clinical and Translational Aspects
18
Journal of Neuropsychopharmacology. 
2017;20:613-618
[96] Nollet M, Gaillard P, Tanti 
A, Girault V, Belzung C, Leman 
S. Neurogenesis-independent 
antidepressant-like effects on behavior 
and stress axis response of a dual orexin 
receptor antagonist in a rodent model of 
depression. Neuropsychopharmacology. 
2012;37:2210-2221
[97] Scott MM, Marcus JN, Pettersen A, 
Birnbaum SG, Mochizuki T, Scammell 
TE, et al. Hcrtr1 and 2 signaling 
differentially regulates depression-like 
behaviors. Behavioural Brain Research. 
2011;222:289-294
